UniProtKB/Swiss-Prot P47871: Variant p.Thr76Met

Glucagon receptor
Gene: GCGR
Feedback?

Variant information Variant position:

76 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Threonine (T) to Methionine (M) at position 76 (T76M, p.Thr76Met). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and polar (T) to medium size and hydrophobic (M) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

No effect on glucagon-elicited cAMP production. Any additional useful information about the variant.

Sequence information Variant position:

76 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

477 The length of the canonical sequence.
Location on the sequence:

LVCNRTFDKYSCWPDTPANT T ANISCPWYLPWHHKVQHRFV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LVCNRTFDKYSCWPDTPANTTANISCPWYLPWHHKVQHRFV

Mouse                         LVCNRTFDKYSCWPDTPPNTTANISCPWYLPWYHKVQHRLV

Rat                           LVCNRTFDKYSCWPDTPPNTTANISCPWYLPWYHKVQHRLV

Pig                           LVCNRTFDKYSCWPDTPPNTTANISCPWYLPWYHKVQHRLV

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	26 – 477	Glucagon receptor
Topological domain	26 – 136	Extracellular
Glycosylation	59 – 59	N-linked (GlcNAc...) asparagine
Glycosylation	74 – 74	N-linked (GlcNAc...) asparagine
Glycosylation	78 – 78	N-linked (GlcNAc...) asparagine
Disulfide bond	58 – 100
Mutagenesis	63 – 63	D -> A. Abolishes glucagon binding.
Mutagenesis	65 – 65	Y -> A. Strongly reduced affinity for glucagon. Increased constitutive signaling via G-proteins.
Beta strand	75 – 80

Literature citations
Characterization of a naturally occurring mutation V368M in the human glucagon receptor and its association with metabolic disorders.
Lin G.; Liu Q.; Dai A.; Cai X.; Zhou Q.; Wang X.; Chen Y.; Ye C.; Li J.; Yang D.; Wang M.W.;
Biochem. J. 477:2581-2594(2020)
Cited for: CHARACTERIZATION OF VARIANTS MVAH HIS-225 AND MET-368; VARIANTS SER-40; MET-76; GLN-336; HIS-414; ARG-416; GLN-428; LEU-438; HIS-458; VAL-461 AND LEU-476; CHARACTERIZATION OF VARIANTS SER-40; MET-76; GLN-336; HIS-414; ARG-416; GLN-428; LEU-438; HIS-458; VAL-461 AND LEU-476; FUNCTION; SUBCELLULAR LOCATION;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.